The use of Chinese herbal medicines associated with reduced mortality in chronic hepatitis B patients receiving lamivudine treatment

详细信息    查看全文

• 作者：Der-Shiang Tsai^a ; Mei-Hsuen Huang^a ; Yuan-Shiun Chang^a ; Tsai-Chung Li^b ; ^c ; Wen-Huang Peng^a ; ^{whpeng@mail.cmu.edu.tw" class="auth_mail" title="E-mail the corresponding author}
• 关键词：CHMs ; Chinese herbal medicines ; CHB ; Chronic hepatitis B ; NHI ; National Health Insurance ; NHIRD ; National Health Insurance Research Database ; JWXYS ; Jia-Wei-Xiao-Yao-San
• 刊名：Journal of Ethnopharmacology
• 出版年：2015
• 出版时间：4 November 2015
• 年：2015
• 卷：174
• 期：Complete
• 页码：161-167
• 全文大小：442 K

文摘

Lamivudine associated mutation and resistance reduces the effect of anti-hepatitis B virus. Pharmacological studies in cell and animal model suggest that Chinese herbal medicines (CHMs) have anti-hepatitis B virus effect. Observational studies offer mixed results. The aim of this study was to evaluate the relation between the use of CHMs and outcome in patients with chronic hepatitis B receiving lamivudine treatment and further estimate the association of Jia-Wei-Xiao-Yao-Sang (JWXYS) use with mortality of those patients.

Materials and methods

We conducted a cohort study among patients age 20–90 years within a National Health Insurance Healthcare system. Information on the use of CHMs and covariates were obtained from Taiwan National Health Insurance Research Database. We used Cox proportional hazards models to estimate the hazard ratio and 95% confidence intervals (95% CI) for all-cause mortality among CHMs users compared to nonusers.

Results

Among 1037 patients studied from 2004 to 2011, median follow-up time 5.3 years and 88 deaths were identified. During the study period, 49% of patients used CHMs and the median duration of use was 2.4 years. We found that significant difference on all-cause mortality among CHMs users (aHR=0.45, 95% CI: 0.27–0.76) compared to CHMs nonusers. All-cause mortality also differed by JWXYS use (aHR=0.26, 95% CI: 0.08–0.83).

Conclusions

This study reveals that the use of CHMs may lower the risk of death in patients with chronic hepatitis B receiving lamivudine treatment. Further randomized-controlled trials are required to validate these findings.